2022
Post-acute sequelae of COVID-19 symptom phenotypes and therapeutic strategies: A prospective, observational study
Frontera JA, Thorpe LE, Simon NM, de Havenon A, Yaghi S, Sabadia SB, Yang D, Lewis A, Melmed K, Balcer LJ, Wisniewski T, Galetta SL. Post-acute sequelae of COVID-19 symptom phenotypes and therapeutic strategies: A prospective, observational study. PLOS ONE 2022, 17: e0275274. PMID: 36174032, PMCID: PMC9521913, DOI: 10.1371/journal.pone.0275274.Peer-Reviewed Original ResearchConceptsPost-acute sequelaeDifferent therapeutic interventionsTherapeutic interventionsTherapeutic strategiesAcute SARS-CoV-2 infectionOccupational therapySARS-CoV-2 infectionOutcome metricsSimilar therapeutic interventionsProspective cohort studyShortness of breathAnti-anxiety medicationsLogistic regression analysisCOVID-19Individual treatment programsPASC symptomsCohort studySymptom improvementUnsupervised hierarchical cluster analysisTreatment strategiesObservational studySleep disordersVariable symptomatologySymptom groupsCognitive symptomsStatin Usage Increases White Matter Hyperintensities
Goldstein ED, Garg G, Navarro K, Wolcott Z, Yaghi S, Wong KH, McLean K, de Havenon AH. Statin Usage Increases White Matter Hyperintensities. The Neurologist 2022, 28: 94-98. PMID: 35680399, DOI: 10.1097/nrl.0000000000000448.Peer-Reviewed Original ResearchMeSH KeywordsDisease ProgressionHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMagnetic Resonance ImagingRisk FactorsWhite MatterConceptsWhite matter hyperintensitiesWMH progressionStatin usageTop tertileRisk factorsMatter hyperintensitiesWMH volumeConventional cerebrovascular risk factorsProgression of WMHCerebral small vessel diseaseInfluence of dyslipidemiaCerebrovascular risk factorsInfluence of statinsBaseline WMH volumeSmall vessel diseaseSynergistic risk factorsLow-density lipoproteinFull therapyStatin useVessel diseaseStudy visitWMH developmentPartial therapyWMH dataReductase inhibitors
2019
Is There Equipoise Regarding the Optimal Medical Treatment of Patients with Asymptomatic White Matter Hyperintensities?
de Havenon A, Prabhakaran S, Turan T, Gottesman R, Yeatts S, Rost N. Is There Equipoise Regarding the Optimal Medical Treatment of Patients with Asymptomatic White Matter Hyperintensities? Journal Of Stroke And Cerebrovascular Diseases 2019, 28: 104371. PMID: 31495669, PMCID: PMC8015436, DOI: 10.1016/j.jstrokecerebrovasdis.2019.104371.Peer-Reviewed Original ResearchMeSH KeywordsAntihypertensive AgentsAsymptomatic DiseasesAttitude of Health PersonnelDisease ProgressionHealth Care SurveysHealth Knowledge, Attitudes, PracticeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLeukoencephalopathiesNeurologistsPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Therapeutic EquipoiseTreatment OutcomeConceptsAsymptomatic white matter hyperintensitiesWhite matter hyperintensitiesOptimal medical treatmentMatter hyperintensitiesMedical treatmentCognitive impairmentIntensive Blood Pressure ReductionNeurologists' attitudesBlood pressure targetsStroke prevention therapyBlood pressure reductionOptimal medical managementRegional coordinating centersMild cognitive impairmentStatin therapyIschemic strokeMicrovascular diseasePressure targetsPrevention therapyClinical outcomesFunctional disabilityMedical managementPatient populationCommon manifestationWMH progressionResults From DEFUSE 3
de Havenon A, Mlynash M, Kim-Tenser MA, Lansberg MG, Leslie-Mazwi T, Christensen S, McTaggart RA, Alexander M, Albers G, Broderick J, Marks MP, Heit JJ, Investigators O. Results From DEFUSE 3. Stroke 2019, 50: 632-638. PMID: 30726184, PMCID: PMC6628906, DOI: 10.1161/strokeaha.118.023407.Peer-Reviewed Original ResearchConceptsIschemic core volumeLarge vessel occlusionEndovascular thrombectomyCollateral statusTomography angiographyFunctional independenceDEFUSE 3Poor collateralsLeptomeningeal collateralsStroke patientsVessel occlusionGood collateralsAnterior circulation large vessel occlusionBaseline ischemic core volumeSmall ischemic core volumeAcute ischemic stroke patientsDEFUSE 3 patientsIschemic stroke patientsModified Rankin ScaleStroke-related deathComputed tomography angiographyGood leptomeningeal collateralsTreatment effectsNeurological outcomePrespecified analysisBlood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics
de Havenon A, Majersik JJ, Tirschwell DL, McNally JS, Stoddard G, Rost NS. Blood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics. Neurology 2019, 92: e1168-e1175. PMID: 30737332, PMCID: PMC6511110, DOI: 10.1212/wnl.0000000000007093.Peer-Reviewed Original ResearchConceptsType 2 diabeticsBlood pressureWhite matter hyperintensitiesRandomization armGlycemic controlWMH progressionHigher systolic blood pressureWhite matter hyperintensity progressionIntensive blood pressureBlood pressure controlSystolic blood pressureHigh blood pressureType 2 diabetesACCORD-MINDComorbid diabetesMacrovascular complicationsCardiovascular riskHemoglobin A1cPrimary outcomeControl armMatter hyperintensitiesAggressive approachWMH volumeControl interventionsPressure control